Buy HUMIRA PEN (Adalimumab) 40mg / 0.8ml

Product Description:

HUMIRA PEN (Adalimumab) 40mg / 0.8ml is a targeted biologic therapy designed to treat various autoimmune conditions by inhibiting tumor necrosis factor-alpha (TNF-alpha), a protein that plays a critical role in inflammatory processes within the body. Each prefilled pen contains 40mg of Adalimumab in 0.8ml solution, ensuring precise and consistent dosing for optimal therapeutic outcomes.

Indications:

HUMIRA is indicated for the treatment of:

• Rheumatoid Arthritis: Moderates severe and active rheumatoid arthritis in adults to reduce symptoms and prevent joint damage.
• Psoriatic Arthritis: Manages signs and symptoms, enhances physical function, and inhibits structural damage in patients with active psoriatic arthritis.
• Ankylosing Spondylitis: Alleviates symptoms in adults with active ankylosing spondylitis.
• Crohn’s Disease: Treats moderate to severe Crohn’s disease in adults and children who have not responded adequately to conventional therapies.
• Ulcerative Colitis: Indicated for adults with moderate to severe ulcerative colitis when other medications have not been effective.
• Plaque Psoriasis: Treats adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
• Juvenile Idiopathic Arthritis: Manages moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.
• Hidradenitis Suppurativa: Indicated for the treatment of moderate to severe hidradenitis suppurativa in adults and adolescents from 12 years of age.
• Uveitis: Treats non-infectious intermediate, posterior, and panuveitis in adult patients.

Mechanism of Action:

Adalimumab is a fully human monoclonal antibody that specifically binds to TNF-alpha, blocking its interaction with TNF receptors on cell surfaces. This inhibition reduces the inflammatory response responsible for autoimmune conditions, leading to decreased symptoms, reduced inflammation, and improved quality of life for patients.

Usage and Administration:

HUMIRA PEN is administered subcutaneously (under the skin) using a prefilled pen for ease and convenience. The pen ensures accurate dosing and reduces the potential for injection errors. Typically, the initial dose and maintenance doses vary based on the condition being treated, and patients should follow the dosing schedule prescribed by their healthcare provider.

Storage and Handling:

• Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Do not freeze.
• Protect from light.
• The pen can be stored at room temperature (up to 25°C/77°F) for a maximum of 14 days. Once stored at room temperature, it should not be placed back in the refrigerator.
• Discard if not used within 14 days at room temperature.

Safety Information:

Patients should be monitored for infections before, during, and after treatment with HUMIRA. It is essential to inform healthcare providers of any history of tuberculosis, chronic infections, or exposure to opportunistic pathogens. The use of HUMIRA may increase the risk of serious infections, including tuberculosis, bacterial sepsis, invasive fungal infections, and other opportunistic infections.

Common Side Effects:

• Injection site reactions (redness, itching, pain)
• Upper respiratory infections
• Headache
• Rash
• Nausea

Precautions:

• Patients should not receive live vaccines while using HUMIRA.
• Regular monitoring of blood counts and liver enzymes is recommended.
• Patients should be educated on recognizing signs of infection and instructed to seek medical advice promptly if symptoms occur.

Conclusion:

HUMIRA PEN (Adalimumab) 40mg / 0.8ml offers a convenient and effective solution for managing various chronic inflammatory conditions. By targeting TNF-alpha, HUMIRA helps reduce inflammation, alleviate symptoms, and improve the quality of life for patients suffering from autoimmune diseases. The prefilled pen format ensures ease of use, making it a preferred choice for both patients and healthcare providers.